Adagene Doses First Patient in Phase 2 Trial of Muzastotug Plus KEYTRUDA for MSS Colorectal Cancer
I'm PortAI, I can summarize articles.
Adagene Inc. has initiated a Phase 2 clinical trial for muzastotug (ADG126) combined with KEYTRUDA® in patients with microsatellite stable colorectal cancer. The trial will randomize patients to receive either 10 mg/kg or 20 mg/kg of muzastotug, with a primary endpoint of overall response rate. Completion is anticipated by early 2027, with updates expected from an ongoing Phase 1b/2 trial. The trial designs align with US FDA requirements.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments